ID: ALA541985

Max Phase: Preclinical

Molecular Formula: C23H39N3O5

Molecular Weight: 437.58

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(C)CCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1

Standard InChI:  InChI=1S/C23H39N3O5/c1-25(2)17-11-9-7-5-3-4-6-8-10-12-22(28)24-21(18-27)23(29)19-13-15-20(16-14-19)26(30)31/h13-16,21,23,27,29H,3-12,17-18H2,1-2H3,(H,24,28)/t21-,23-/m1/s1

Standard InChI Key:  XXIDLBHGCBHNCF-FYYLOGMGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 437.58

Molecular Weight (Monoisotopic): 437.2890

AlogP: 3.57

#Rotatable Bonds: 17

Polar Surface Area: 115.94

Molecular Species: BASE

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.88

CX Basic pKa: 9.79

CX LogP: 3.57

CX LogD: 1.21

Aromatic Rings: 1

Heavy Atoms: 31

QED Weighted: 0.19

Np Likeness Score: -0.34

References

1. Bai A, Szulc ZM, Bielawski J, Mayroo N, Liu X, Norris J, Hannun YA, Bielawska A..  (2009)  Synthesis and bioevaluation of omega-N-amino analogs of B13.,  17  (5): [PMID:19217788] [10.1016/j.bmc.2009.01.057]

2. Bhabak KP, Kleuser B, Huwiler A, Arenz C..  (2013)  Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.,  21  (4): [PMID:23312611] [10.1016/j.bmc.2012.12.014]

Source

Source(1):

• Scientific Literature